Table 1.
Clinical characteristics of children >60 days with cerebrospinal fluid tested for suspected central nervous system infection in the Children’s Hospital Colorado microbiology laboratory.
| Characteristic | Pre-MEP era (n = 4888) | MEP Era (n = 408) | P |
|---|---|---|---|
| Age (median years: IQR) | 5 (1. 13) | 6(1. 13) | 0.134 |
| 2–6 months | 997 (20%) | 75 (18%) | 0.354 |
| 6 months-1 year | 430 (9%) | 28 (7%) | |
| 1-4 years | 938 (19%) | 81 (20%) | |
| >=4 years | 2523 (52%) | 224 (55%) | |
| Male | 2479 (51%) | 199 (49%) | 0.35 |
| White Race | 3159 (67%) | 264 (66%) | 0.933 |
| CSF Pleocytosis (> 5 WBCs) | 1048 (24%) | 106 (28%) | 0.097 |
| Positive CSF Bacterial Culture* | 70 (1%) | 6 (2%) | 1 |
| Positive CSF Enterovirus Test* | 153 (10%) | 11 (5%) | 0.033 |
| CSF Tested for HSV (MEP or HSV PCR) | 1225 (25%) | 219 (54%) | <0.0001 |
| Tested by HSV PCR | 1225 (25%) | 18 (4%) | <0.0001 |
| Tested by MEP | 0 (0%) | 211 (52%) | <0.0001 |
| Positive CSF HSV Test* | 8 (0.6%) | 0 (0%) | 0.23 |
| Tested for HSV with CSF WBC <5/μL | 720 (63%) | 121 (59%) | 0.27 |
| Received acyclovir** | 648 (13%) | 48 (12%) | 0.43 |
| Median doses of acyclovir (IQR)** | 5 (3.8) | 3(1.9) | 0.05 |
Denominator includes only those tested.
Excludes the 8 children with positive CSF HSV tests in the pre-MEP era.